Bli medlem
Bli medlem

Du är här

2016-12-22

SciBase: SciBase increases the information flow to shareholders with a regular letter from the CEO

To keep shareholders and other interested parties updated about
SciBase progress we have we have decided to start sending out regular
short newsletters regarding company activities and market
information. In these letters we will explain important events in the
Company's development in a little more detail and touch upon current
events within our industry or in the field of skin cancer. Please
sign up for this newsletter here (http://eepurl.com/ct-1sn).

In this first letter we thought we'd outline our view on one of this
autumn's hot topics - teledermoscopy, and discuss how this method
relates to our instrument.

Teledermoscopy - good for increased awareness and access but is it
good enough as a diagnostic method?

Cancer is a disease that affects us all. It is estimated that a third
of all Swedes will at some time in their lives receive a cancer
diagnosis. One of the fastest growing cancers is skin cancer, of
which malignant melanoma is the most dangerous type. Our instrument
Nevisense, complements a traditional visual examination with a direct
physical measurement of a lesion's structure via its impedance. This
helps physicians objectively assess suspicious lesions directly on
the skin, i.e. without having to surgically excise the lesion of
concern. With the help of Nevisense a physician can potentially
detect melanoma at an earlier stage in its development, while
decreasing the number of unnecessary surgeries to excise suspicious
lesions. The earlier that cancer can be detected the higher the
survival rate will be.

In recent times much has been written about teledermoscopy, a method
to evaluate suspected skin cancer based on the remote evaluation of
lesion images. Teledermoscopy means taking a picture of a suspicious
lesion then sending the image and patient's clinical data to a
specialist for interpretation. The patient later receives advice on
how to proceed, usually whether or not the patient needs to visit a
physician for a `physical' examination.

There are different variants of teledermoscopy. On the consumer
(public) market there are apps that can be installed on your
smartphone. Through the app you take a picture of a lesion and then
send it for interpretation by (usually) a Dermatologist. The
assessment usually costs from a few hundred crowns, and you usually
receive a response within 24 hours to two weeks.

The healthcare sector has generally also embraced the method, which
means that many primary care centers and General Practitioners have
the possibility to send a picture to a specialist for assessment.
This is something that takes place for example, in Stockholms Läns
Landsting. Study results indicate that teledermoscopy results in
shorter waiting times compared to the normal wait to see a
Dermatologist.

Teledermoscopy improves patient access to an examination and can
result in the patient receiving care earlier, which is good. The
earlier we detect malignant melanoma the better the chance to treat
it successfully. When it comes to teledermoscopy for consumers there
is however a risk with patients themselves selecting which lesion or
lesions are to be assessed. The risk is that they choose benign
lesion(s) for evaluation while missing the lesion that is a melanoma
or other type of skin cancer. In addition a recent review published
in JAMA Dermatology [1]
(http://file:///G:/1030%20Economy/VD%20brev/CEOletter-ENG_FINAL%20161222....)
showed that in general assessment by a Dermatologist during a face to
face consultation results in a more accurate assessment than one done
by teledermoscopy. It is therefore advantageous for patients to
utilise face to face assessment by a physician who performs a full
examination.

The products that cater to the consumer do however contribute with an
important factor, to increase awareness which can lead to an
increased patient flow into the health care system. To be able to
handle the increased number of patients with lesions of concern, the
health care system needs to be improved and streamlined. This is
where SciBase comes in. As greater numbers of suspicious lesions are
being evaluated, diagnosis needs to be as efficient and effective as
possible. Diagnosis often involves excision of a suspected lesion,
yet we know that 93-97 percent of all excisions are unnecessary as
the excised tissue is not cancerous. Utilising Nevisense can reduce
the number of unnecessary excisions by up to 40 percent. In addition
to saving money for the healthcare system by performing fewer
operations and pathology evaluations, we reduce patient anxiety and
discomfort. Whereas Nevisense provides an immediate answer, excisions
and biopsies must be analysed by a pathologist to determine if they
are malignant or not. In the worst case it can take up to eight weeks
to get an answer, a wait that can be hard on the patient.

Nevisense is therefore a good complement to the diagnostic process
both in situations with or without teledermoscopy. The challenge for
Scibase is to demonstrate that Nevisense can help streamline the
diagnostic process, save money and provide better care to patients.
We are well on the way with a number of studies. A recent Australian
study shows that Nevisense can halve the number of patients that need
to undergo sequential monitoring i.e. that need to have a follow-up
visit with digital dermoscopy. This is just one example of how
Nevisense can lead to substantial cost-savings.

Launch of Nevisense View

Finally, in response to our customers demand, we are expanding the
functionality of Nevisense and launching an additional product -
Nevisense View. With Nevisense View we have integrated clinical and
dermoscopic images with our patented impedance technology. This new
product was developed for clinicians that want to combine both
methods and improve the management of patients. The first shipments
to customers start now in December 2016. In the next CEO letter we
will discuss Nevisense View and its application in more detail.

Merry Christmas and a Happy New Year!

For further information please visit www.scibase.com or contact:

Simon Grant, CEO
Tel: +46 72 887 43 99
E-mail: simon.grant@scibase.com

About Skin Cancer
Skin cancer is one of the world's most common cancers, accounting for
nearly half of all cancers. It has been estimated that nearly half of
all Americans who live to the age of 65 will develop skin cancer at
least once. Malignant melanoma is the most fatal form of skin cancer
causing the majority (75%) of deaths related to skin cancer.
Worldwide, doctors diagnose about 230,000 new cases of melanoma
yearly.

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in
Stockholm that has developed a unique point-of-care device for the
accurate detection of malignant melanoma. Its product, Nevisense,
helps doctors to detect malignant melanoma, the most dangerous type
of skin cancer. SciBase was founded by Stig Ollmar, Associate
Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense
is based on substantial research and has achieved excellent results
in the largest clinical study ever conducted on the detection of
malignant melanoma. Nevisense is CE marked in Europe, has TGA
approval in Australia, and is awaiting FDA clearance in the United
States. Nevisense is based on a method called Electrical Impedance
Spectroscopy (EIS), which uses the varying electrical properties of
human tissue to categorize cellular structures and thereby detect
malignancies. SciBase is listed on Nasdaq First North ("SCIB").
Avanza is the certified advisor. Further information is available on
www.scibase.com.

----------------------------------------------------------------------

[1]
(http://file:///G:/1030%20Economy/VD%20brev/CEOletter-ENG_FINAL%20161222....)
Finnane A Soyer P et al. Teledermatology for the Diagnosis and
Management of Skin Cancer. A Systematic Review. JAMA Dermatology.
Dec. 2016

-----------------------------------------------------------
http://news.cision.com/scibase/r/scibase-increases-the-information-flow-...
http://mb.cision.com/Main/12371/2155960/607731.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.